Αρχική World News EMA Recommends Granting a Marketing Authorisation for Senaparib World News EMA Recommends Granting a Marketing Authorisation for Senaparib Από Ogkologos - 15 Οκτωβρίου, 2026 301 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the maintenance treatment of advanced epithelial ovarian, Fallopian tube and primary peritoneal cancer Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR This Program Provides Free Mammograms And Breast Cancer Treatment Services To... 9 Οκτωβρίου, 2019 ESMO Asia Virtual Congress 2020, 20-22 November 26 Οκτωβρίου, 2020 Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer 3 Ιανουαρίου, 2024 Cancer-impacted mother becomes Times Square billboard to help child come across... 21 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Re-Thinking Community What Is Peripheral Neuropathy and How Can It Be Prevented or... Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced... As Use of Genomic Data Expands in Cancer Care, Patients Share...
